Fed’s Powell opens door to potential rate cuts at Jackson Hole
SAN FRANCISCO—Hims & Hers Health, Inc. (NYSE:HIMS) reported a significant stock transaction involving its Chief Commercial Officer, Michael Chi. According to a recent SEC filing, Chi sold 7,500 shares of Class A Common Stock on February 19, 2025, at a price of $59.26 per share, totaling approximately $444,450.
On the same day, Chi also exercised stock options to acquire 7,500 shares at a price of $13.90 per share. This transaction was part of a pre-established Rule 10b5-1 trading plan, adopted on March 1, 2024. Following these transactions, Chi holds 193,601 shares directly. The company maintains strong financial health with a current ratio of 2.14 and operates with minimal debt, as revealed by InvestingPro’s comprehensive analysis, which includes 18 additional key insights available to subscribers.
The options exercised are subject to a service-based vesting schedule, with full vesting achieved over a four-year period. The company has demonstrated robust growth, with revenue increasing by 56.7% in the last twelve months and maintaining an impressive gross profit margin of 81.1%.
In other recent news, Hims & Hers Health, Inc. has reported significant developments that may interest investors. The company recently announced a 104% year-over-year increase in online sales for January, with GLP-1 drugs accounting for about 40% of its gross online sales. Analysts at BofA Securities project online revenue for the first quarter of 2025 to range between $551 million and $574 million, surpassing the consensus estimate of $489.4 million. Despite this growth, BofA maintains an Underperform rating on the stock, albeit with a raised price target of $21.
Additionally, Hims & Hers has acquired Trybe Labs, an at-home lab testing facility, to enhance its platform with personalized healthcare services. This acquisition will enable the company to offer comprehensive at-home testing, which is expected to improve clinical decision-making and support personalized treatments. Following this development, Canaccord Genuity raised its price target for Hims & Hers to $68, maintaining a Buy rating, while BTIG also increased its target to $85, citing positive market performance and trends in the direct-to-consumer health sector.
These updates reflect a period of strategic growth and expansion for Hims & Hers, as the company continues to broaden its healthcare offerings. The acquisition and the increased analyst price targets underscore the company’s potential to capitalize on current market trends. Investors will be closely watching how these strategic moves impact Hims & Hers’ financial performance in the coming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.